Published in J Infect Dis on February 01, 2010
A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 | NCT04809389
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS One (2015) 1.39
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One (2011) 1.14
NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine (2010) 1.08
New vaccines against influenza virus. Clin Exp Vaccine Res (2013) 1.04
NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge. J Virol (2012) 0.95
Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines (2012) 0.91
Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One (2012) 0.89
Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int (2015) 0.89
Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J Gen Virol (2010) 0.88
Attenuated influenza virus construct with enhanced hemagglutinin protein expression. J Virol (2012) 0.86
Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Med Microbiol Immunol (2009) 0.86
Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. J Virol (2010) 0.85
Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. J Virol (2011) 0.83
Translational research in infectious disease: current paradigms and challenges ahead. Transl Res (2012) 0.83
Mutations in the M-gene segment can substantially increase replication efficiency of NS1 deletion influenza A virus in MDCK cells. J Virol (2012) 0.82
The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study. Results Immunol (2012) 0.81
Recombinant influenza vaccines. Acta Naturae (2012) 0.80
Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells. BMC Biotechnol (2011) 0.78
An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus. Vaccine (2011) 0.78
IL-24 sensitizes tumor cells to TLR3-mediated apoptosis. Cell Death Differ (2013) 0.77
Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J (2014) 0.77
Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs. Clin Vaccine Immunol (2015) 0.76
Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus. PLoS One (2016) 0.75
Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice. Clin Vaccine Immunol (2015) 0.75
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) (2016) 0.75
Nonstructural protein 11 (nsp11) of porcine reproductive and respiratory syndrome virus (PRRSV) promotes PRRSV infection in MARC-145 cells. BMC Vet Res (2016) 0.75
Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase. Mol Ther Oncolytics (2017) 0.75
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum (2006) 2.57
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci (2002) 2.32
Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. Ochsner J (2012) 2.29
Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups. J Clin Microbiol (2002) 2.13
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09
Osteoarthritis - an untreatable disease? Nat Rev Drug Discov (2005) 1.93
Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke (2002) 1.88
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Single versus dual respiratory virus infections in hospitalized infants: impact on clinical course of disease and interferon-gamma response. Pediatr Infect Dis J (2005) 1.72
Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology (2003) 1.70
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol (2009) 1.60
Qualitative and quantitative assessment of nailfold capillaries by capillaroscopy in healthy volunteers. Vasa (2012) 1.57
Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev (2002) 1.54
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther (2008) 1.54
Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release (2003) 1.54
Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J (2005) 1.50
Cell phones and brain tumors: a review including the long-term epidemiologic data. Surg Neurol (2009) 1.50
The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia (2009) 1.49
Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur J Pediatr (2004) 1.48
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol (2004) 1.41
Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol (2003) 1.39
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev (2005) 1.38
Assessing lung function and respiratory health in schoolchildren as a means to improve local environmental conditions. J Public Health Policy (2009) 1.38
Field effectiveness of vaccination against tick-borne encephalitis. Vaccine (2007) 1.37
Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol (2010) 1.36
The clinical value of neutrophil extracellular traps. Med Microbiol Immunol (2009) 1.34
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res (2009) 1.34
Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci U S A (2005) 1.33
Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol (2010) 1.31
An international external quality assessment of nucleic acid amplification of herpes simplex virus. J Clin Virol (2003) 1.30
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation (2007) 1.29
Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J (2010) 1.28
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci (2004) 1.24
Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine (2011) 1.24
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther (2008) 1.22
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett (2007) 1.20
Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis (2013) 1.20
Mesh graft infection following abdominal hernia repair: risk factor evaluation and strategies of mesh graft preservation. A retrospective analysis of 476 operations. World J Surg (2010) 1.20
Burst discharge in primary sensory neurons: triggered by subthreshold oscillations, maintained by depolarizing afterpotentials. J Neurosci (2002) 1.17
N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol (2009) 1.16
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One (2011) 1.14
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum (2010) 1.14
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer (2003) 1.12
Valproic acid as anti-cancer drug. Curr Pharm Des (2007) 1.11
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother (2007) 1.11
Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res (2010) 1.10
Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses. Med Microbiol Immunol (2010) 1.09
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol (2009) 1.09
Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis (2003) 1.09
Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol (2011) 1.08
Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients. Transplantation (2006) 1.08
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol (2005) 1.08
Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica (2010) 1.08
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res (2011) 1.06
The threat of avian influenza A (H5N1). Part IV: Development of vaccines. Med Microbiol Immunol (2007) 1.06
Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One (2011) 1.06
Determination of risk of infection with blood-borne pathogens following a needlestick injury in hospital workers. Ann Occup Hyg (2008) 1.05
Effect of staining procedures on the results of micronucleus assays with exfoliated oral mucosa cells. Cancer Epidemiol Biomarkers Prev (2006) 1.05
Neutrophils and the blood-brain barrier dysfunction after trauma. Med Res Rev (2007) 1.04
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One (2009) 1.04
Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol (2004) 1.03
Dimensions of engorging Ixodes ricinus as a measure of feeding duration. Int J Med Microbiol (2005) 1.02
Mobile telephones and cancer: is there really no evidence of an association? (review). Int J Mol Med (2003) 1.02
Inhibition of apoptosis prevents West Nile virus induced cell death. BMC Microbiol (2007) 1.02